These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 19237229)

  • 1. New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3.
    Stefane B; Brozic P; Vehovc M; Rizner TL; Gobec S
    Eur J Med Chem; 2009 Jun; 44(6):2563-71. PubMed ID: 19237229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonsteroidal anti-inflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: new lead compounds for the development of anticancer agents.
    Gobec S; Brozic P; Rizner TL
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5170-5. PubMed ID: 16183274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3.
    Beranič N; Gobec S; Rižner TL
    Chem Biol Interact; 2011 May; 191(1-3):227-33. PubMed ID: 21182831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2,3-Diarylpropenoic acids as selective non-steroidal inhibitors of type-5 17β-hydroxysteroid dehydrogenase (AKR1C3).
    Gazvoda M; Beranič N; Turk S; Burja B; Kočevar M; Rižner TL; Gobec S; Polanc S
    Eur J Med Chem; 2013 Apr; 62():89-97. PubMed ID: 23353746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-Benzoyl anthranilic acid derivatives as selective inhibitors of aldo-keto reductase AKR1C3.
    Sinreih M; Sosič I; Beranič N; Turk S; Adeniji AO; Penning TM; Rižner TL; Gobec S
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5948-51. PubMed ID: 22897946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors.
    Penning TM; Steckelbroeck S; Bauman DR; Miller MW; Jin Y; Peehl DM; Fung KM; Lin HK
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):182-91. PubMed ID: 16417966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New enzymatic assay for the AKR1C enzymes.
    Beranič N; Stefane B; Brus B; Gobec S; Rižner TL
    Chem Biol Interact; 2013 Feb; 202(1-3):204-9. PubMed ID: 23261716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids.
    Skarydová L; Zivná L; Xiong G; Maser E; Wsól V
    Chem Biol Interact; 2009 Mar; 178(1-3):138-44. PubMed ID: 19007764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective inhibitors of aldo-keto reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment library.
    Brožič P; Turk S; Adeniji AO; Konc J; Janežič D; Penning TM; Lanišnik Rižner T; Gobec S
    J Med Chem; 2012 Sep; 55(17):7417-24. PubMed ID: 22881866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro inhibition of AKR1Cs by sulphonylureas and the structural basis.
    Zhao Y; Zheng X; Zhang H; Zhai J; Zhang L; Li C; Zeng K; Chen Y; Li Q; Hu X
    Chem Biol Interact; 2015 Oct; 240():310-5. PubMed ID: 26362498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of non-prenyl analogues of baccharin as selective and potent inhibitors for aldo-keto reductase 1C3.
    Endo S; Hu D; Matsunaga T; Otsuji Y; El-Kabbani O; Kandeel M; Ikari A; Hara A; Kitade Y; Toyooka N
    Bioorg Med Chem; 2014 Oct; 22(19):5220-33. PubMed ID: 25182963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3.
    Heinrich DM; Flanagan JU; Jamieson SM; Silva S; Rigoreau LJ; Trivier E; Raynham T; Turnbull AP; Denny WA
    Eur J Med Chem; 2013 Apr; 62():738-44. PubMed ID: 23454516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective inhibition of human type-5 17β-hydroxysteroid dehydrogenase (AKR1C3) by baccharin, a component of Brazilian propolis.
    Endo S; Matsunaga T; Kanamori A; Otsuji Y; Nagai H; Sundaram K; El-Kabbani O; Toyooka N; Ohta S; Hara A
    J Nat Prod; 2012 Apr; 75(4):716-21. PubMed ID: 22506594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships.
    Adeniji AO; Twenter BM; Byrns MC; Jin Y; Chen M; Winkler JD; Penning TM
    J Med Chem; 2012 Mar; 55(5):2311-23. PubMed ID: 22263837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel potent macrocyclic inhibitors of the hepatitis C virus NS3 protease: use of cyclopentane and cyclopentene P2-motifs.
    Bäck M; Johansson PO; Wångsell F; Thorstensson F; Kvarnström I; Ayesa S; Wähling H; Pelcman M; Jansson K; Lindström S; Wallberg H; Classon B; Rydergård C; Vrang L; Hamelink E; Hallberg A; Rosenquist S; Samuelsson B
    Bioorg Med Chem; 2007 Nov; 15(22):7184-202. PubMed ID: 17845856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular docking simulations of steroid substrates into human cytosolic hydroxysteroid dehydrogenases (AKR1C1 and AKR1C2): insights into positional and stereochemical preferences.
    Jin Y; Penning TM
    Steroids; 2006 May; 71(5):380-91. PubMed ID: 16455123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer.
    Rizner TL; Smuc T; Rupreht R; Sinkovec J; Penning TM
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):126-35. PubMed ID: 16338060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic Acids: highly potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase AKR1C3.
    Jamieson SM; Brooke DG; Heinrich D; Atwell GJ; Silva S; Hamilton EJ; Turnbull AP; Rigoreau LJ; Trivier E; Soudy C; Samlal SS; Owen PJ; Schroeder E; Raynham T; Flanagan JU; Denny WA
    J Med Chem; 2012 Sep; 55(17):7746-58. PubMed ID: 22877157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ruthenium complexes as inhibitors of the aldo-keto reductases AKR1C1-1C3.
    Traven K; Sinreih M; Stojan J; Seršen S; Kljun J; Bezenšek J; Stanovnik B; Turel I; Rižner TL
    Chem Biol Interact; 2015 Jun; 234():349-59. PubMed ID: 25446855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase (AKR1C3).
    Flanagan JU; Atwell GJ; Heinrich DM; Brooke DG; Silva S; Rigoreau LJ; Trivier E; Turnbull AP; Raynham T; Jamieson SM; Denny WA
    Bioorg Med Chem; 2014 Feb; 22(3):967-77. PubMed ID: 24411201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.